In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 12, 2014, Pages 4542-4547

  Sagiyama, Koji ^a   Mashimo, Tomoyuki ^b,c   Togao, Osamu ^a   Vemireddy, Vamsidhara ^b,c   Hatanpaa, Kimmo J ^b   Maher, Elizabeth A ^b,c   Mickey, Bruce E ^b   Pan, Edward ^b,c   Sherry, A Dean ^a,b   Bachoo, Robert M ^b,c   Takahashi, Masaya ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Chemical exchange transfer imaging; Chemoresistance; Molecular MRI

Indexed keywords

AMIDE; BIOLOGICAL MARKER; KI 67 ANTIGEN; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CELL DENSITY; CONTROLLED STUDY; GLIOBLASTOMA; IN VIVO STUDY; LONGITUDINAL STUDY; METABOLITE; MOUSE; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; PROTON TRANSPORT; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VOLUME;

CHEMICAL EXCHANGE TRANSFER IMAGING; CHEMORESISTANCE; MOLECULAR MRI;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; GLIOBLASTOMA; HUMANS; MICE; MICE, SCID; PROGNOSIS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896911544     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1323855111     Document Type: Article

References (47)

1. Stupp R, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996. (Pubitemid 40349501)
2. Choi C, et al. (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18(4):624-629.
3. Thomas RP, Recht L, Nagpal S (2013) Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clin Pharmacol 5:1-9.
4. Matsuda K, et al. (2012) Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. Sci Rep 2:516.
5. Stupp R, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459-466.
6. Hegi ME, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003. (Pubitemid 40349502)
7. Mrugala MM, Chamberlain MC (2008) Mechanisms of disease: Temozolomide and glioblastoma - look to the future. Nat Clin Pract Oncol 5(8):476-486.
8. Johannessen TC, Bjerkvig R (2012) Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther 12(5):635-642.
9. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492-507.
10. Waldman AD, et al.; National Cancer Research Institute Brain Tumour Imaging Subgroup (2009) Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol 6(8):445-454.
11. Fellner F, Fellner C, Held P, Schmitt R (1997) Comparison of spin-echo MR pulse sequences for imaging of the brain. AJNR Am J Neuroradiol 18(9):1617-1625. (Pubitemid 30399760)
12. van Zijl PC, Jones CK, Ren J, Malloy CR, Sherry AD (2007) MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). Proc Natl Acad Sci USA 104(11):4359-4364. (Pubitemid 47186231)
13. Mani T, et al. (2009) Modulation of water exchange in Eu(III) DOTA-tetraamide complexes: considerations for in vivo imaging of PARACEST agents. Contrast Media Mol Imaging 4(4):183-191.
14. Ren J, Trokowski R, Zhang S,Malloy CR, Sherry AD (2008) Imaging the tissue distribution of glucose in livers using a PARACEST sensor. Magn Reson Med 60(5):1047-1055.
15. Zhou J, Lal B, Wilson DA, Laterra J, van Zijl PC (2003) Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med 50(6):1120-1126. (Pubitemid 37494013)
16. Salhotra A, et al. (2008) Amide proton transfer imaging of 9L gliosarcoma and human glioblastoma xenografts. NMR Biomed 21(5):489-497. (Pubitemid 351895437)
17. Zhou J, et al. (2008) Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med 60(4):842-849.
18. Togao O, et al. (2014) Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. Neuro-oncol 16(3):441-448.
19. Zhou J, et al. (2011) Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med 17(1):130-134.
20. Marian CO, et al. (2010) The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 16(1):154-163.
21. Marin-Valencia I, et al. (2012) Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. NMR Biomed 25(10):1177-1186.
22. Fisher ER, et al. (2002) Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95(4):681-695. (Pubitemid 34845919)
23. McCluggage WG, et al. (2002) Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 55(1):27-31. (Pubitemid 34081677)
24. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453-461. (Pubitemid 351597795)
25. Hygino da Cruz LC, Jr., Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: Imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32(11):1978-1985.
26. Fink J, Born D, Chamberlain MC (2011) Pseudoprogression: Relevance with respect to treatment of high-grade gliomas. Curr Treat Options Oncol 12(3):240-252.
27. Alexiou GA, et al. (2009) Glioma recurrence versus radiation necrosis: Accuracy of current imaging modalities. J Neurooncol 95(1):1-11.
28. van Zijl PC, et al. (2003) Mechanism of magnetization transfer during on-resonance water saturation. A new approach to detect mobile proteins, peptides, and lipids. Magn Reson Med 49(3):440-449.
29. Howe FA, et al. (2003) Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 49(2):223-232. (Pubitemid 36159858)
30. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab Press, Cold Spring Harbor, NY), 2nd Ed.
31. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11(2):85-95.
32. Togao O, et al. (2013) Characterization of lung cancer by amide proton transfer (APT) imaging: An in-vivo study in an orthotopic mouse model. PLoS ONE 8(10):e77019.
33. Chen W, et al. (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 25(30):4714-4721. (Pubitemid 350086472)
34. Rock KL, York IA, Saric T, Goldberg AL (2002) Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 80:1-70. (Pubitemid 34625620)
35. Burger AM, Seth AK (2004) The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications. Eur J Cancer 40(15):2217-2229. (Pubitemid 39348871)
36. Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC (2003) Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med 9(8):1085-1090. (Pubitemid 37021791)
37. Hideshima T, Bradner JE, Chauhan D, Anderson KC (2005) Intracellular protein degradation and its therapeutic implications. Clin Cancer Res 11(24 pt 1):8530-8533. (Pubitemid 43005896)
38. Izumi H, et al. (2003) Cellular pH regulators: Potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 29(6):541-549. (Pubitemid 37428326)
39. Affar B, Shah RG, Dallaire AK, Castonguay V, Shah GM (2002) Role of poly(ADP-ribose) polymerase in rapid intracellular acidification induced by alkylating DNA damage. Proc Natl Acad Sci USA 99(1):245-250. (Pubitemid 34060348)
40. Barry MA, Reynolds JE, Eastman A (1993) Etoposide-induced apoptosis in human HL-60 cells is associated with intracellular acidification. Cancer Res 53(10, suppl):2349-2357. (Pubitemid 23156824)
41. Goossens JF, Hénichart JP, Dassonneville L, Facompré M, Bailly C (2000) Relation between intracellular acidification and camptothecin-induced apoptosis in leukemia cells. Eur J Pharm Sci 10(2):125-131. (Pubitemid 30155934)
42. Nath K, et al. (2013) (31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. NMR Biomed 26(1):98-105.
43. Wen ZB, et al. (2010) MR imaging of high-grade brain tumors using endogenous protein and peptide-based contrast. Neuroimage 51(2):616-622.
44. Klomp DW, et al. (2013) Amide proton transfer imaging of the human breast at 7T: Development and reproducibility. NMR Biomed 26(10):1271-1277.
45. Vinogradov E, Sherry AD, Lenkinski RE (2013) CEST: From basic principles to applications, challenges and opportunities. J Magn Reson 229:155-172.
46. Takahashi M, Uematsu H, Hatabu H (2003) MR imaging at high magnetic fields. Eur J Radiol 46(1):45-52. (Pubitemid 36332078)
47. Jones CK, et al. (2006) Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med 56(3):585-592. (Pubitemid 44338877)